Minerva Neurosciences (Minerva Neurosciences) Market Cap : $16.50 Mil (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Minerva Neurosciences's share price for the quarter that ended in Dec. 2023 was $6.15. Minerva Neurosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 6.99 Mil. Therefore, Minerva Neurosciences's market cap for the quarter that ended in Dec. 2023 was $43.01 Mil.

Minerva Neurosciences's quarterly market cap declined from Jun. 2023 ($63.92 Mil) to Sep. 2023 ($48.25 Mil) and declined from Sep. 2023 ($48.25 Mil) to Dec. 2023 ($43.01 Mil).

Minerva Neurosciences's annual market cap declined from Dec. 2021 ($34.22 Mil) to Dec. 2022 ($8.49 Mil) but then increased from Dec. 2022 ($8.49 Mil) to Dec. 2023 ($43.01 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Minerva Neurosciences's Enterprise Value for Today is $-24.06 Mil.

Minerva Neurosciences Market Cap Historical Data

The historical data trend for Minerva Neurosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Market Cap Chart

Minerva Neurosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

277.89

99.97

34.22

8.49

43.01

Minerva Neurosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															8.49	8.54	63.92	48.25	43.01

Competitive Comparison of Minerva Neurosciences's Market Cap

For the Biotechnology subindustry, Minerva Neurosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Market Cap falls into.

Minerva Neurosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Minerva Neurosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$6.15	*	6.99341
	=	$43.01

Minerva Neurosciences's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$6.15	*	6.99341
	=	$43.01

Minerva Neurosciences (NAS:NERV) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Minerva Neurosciences Market Cap Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Neurosciences (Minerva Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

4MNA:Germany 4MNA:Germany

Address

1500 District Avenue, Burlington, MA, USA, 01803

Website

https://www.minervaneurosciences.com

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Executives

Ag Boehringer	10 percent owner	BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh	10 percent owner	200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer	officer: EVP and Head of R&D	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race	officer: EVP and CFO	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm	officer: Chief Accounting Officer	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly	officer: Chief Business Officer	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell	officer: President	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle	director
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd	10 percent owner	5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd	10 percent owner	44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG